This link will take you to a page that’s not on LinkedIn

Because this is an external link, we’re unable to verify it for safety.

https://www.curis.com/study/a-study-of-emavusertib-an-approved-bruton-tyrosine-kinase-inhibitor-btki-in-participants-with-chronic-lymphocytic-leukemia-cll-and-other-b-cell-malignancies/